NCT03419442View on ClinicalTrials.gov

Multi-academic Center Study of Xofigo Patients

CompletedOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

December 3, 2018

Primary Completion Date

October 22, 2019

Study Completion Date

October 22, 2019

Conditions
Prostate Cancer, Castration Resistant
Interventions
DRUG

Xofigo

Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injection

DRUG

Taxotere

Docetaxel injection 75mg/m2 every 3 weeks

DRUG

Jevtana

Cabazitaxel injection 25mg/m2 intravenously once every 3 weeks

Trial Locations (1)

07981

Bayer US, Whippany

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY